ABBV - Barclays cuts ImmunoGen to equal weight doesn't see more bidders
2023-12-04 16:18:03 ET
More on ImmunoGen
- AbbVie: Risky Purchase Of ImmunoGen Could Pay Off Big Time
- Immunogen's AbbVie Deal: Key Insights For Investors And Traders
- AbbVie Bets Big On ImmunoGen: A $10 Billion Leap Into Ovarian Oncology
- Biotechs post record gains in November amid improving outlook
- ImmunoGen downgraded on Wall Street expecting AbbVie deal success
For further details see:
Barclays cuts ImmunoGen to equal weight, doesn't see more bidders